Pharmacist News & Journals – Pharmacy Articles

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 email addresses.
*From Email:
*To Email:
To Email:
To Email:
To Email:
To Email:

New Study Evaluating the ADHD Medication VYVANSE (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor
Shire plc, the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE CII with the proton pump inhibitor Prilosec OTC 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of Prilosec OTC with ADDERALL XR resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters of active medication were not altered for either VYVANSE or ADDERALL XR when coadministered with Prilosec OTC. [more...]

Shire

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine

Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics

Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor